HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kilbourn, M. R. Articles by Zalutsky, M. R. Search for Related Content PubMed PubMed Citation Articles by Kilbourn, M. R. Articles by Zalutsky, M. R.

Research and Clinical Potential of Receptor Based Radiopharmaceuticals^*

Division of Radiation Sciences, Washington University School of Medicine, St. Louis, Missouri
Harvard Medical School, Boston, Massachusetts

Correspondence: For reprints contact: Michael R. Kilbourn, PhD, Division of Radiation Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway, St. Louis, MO 63110.

ABSTRACT

Receptors are proteins that have specific binding affinity for substances that produce a physiological event in the body. Receptor-binding radiotracers are being used increasingly to study the function of receptors in health and disease. This review summarizes the proceedings of a symposium on research in the development of receptor-binding radiopharmaceuticals. The key phases in this research include: (1) selection of the receptor system and ligand; (2) synthesis of radiolabeled ligand; (3) validation in animal models; and (4) clinical application. Current research involves a variety of biological systems, such as butyrophenone neuroleptics for dopamine receptors and steroidal estrogens for the estrogen receptor. In the future, it is believed that receptor-binding radiopharmaceuticals will be useful, not only to validate receptor systems in vivo, but also to aid in the diagnosis and therapy of human diseases.

FOOTNOTES

^* This work was based on a symposium held at the 4th Conjoint Winter Meeting of The Society of Nuclear Medicine, January 1985, and sponsored by the Department of Energy (Grant P8406043). Invited speakers were Dr. John Katzenellenbogen, University of Illinois; Dr. Michael J. Welch, Washington University, Dr. Alfred P. Wolf, Brookhaven National Laboratory; Dr. William C. Eckelman, National Institutes of Health; Dr. Dominique Comar, Service Hospitalier Frederic Joliot (Orsay, France); Dr. Marcus E. Raichle, Washington University; Dr. Henry N. Wagner, Jr., Johns Hopkins; and Dr. Robert Stadalnik, University of California, Davis.